The short answer
Hepatic safety is a question for oral small-molecule GLP-1 agonists in a way it was not for injectable peptides, because small molecules are metabolised by liver enzyme systems that peptides largely bypass. One programme, danuglipron, has already been discontinued over a single liver injury case.
Key facts
- Peptide GLP-1s
- Cleared by proteolysis and renal routes
- Small molecules
- Hepatic enzyme metabolism
- Danuglipron
- Discontinued April 2025 over one DILI case
- Aleniglipron ACCESS
- No cases of drug-induced liver injury
- Orforglipron
- Approved (UK, August 2026)
- Why it matters more here
- Chronic use, large populations
Why peptides did not raise this question
Semaglutide, tirzepatide and retatrutide are peptides. They are broken down by proteases into amino acids and cleared through routes that do not depend heavily on hepatic enzyme metabolism. There is no reactive metabolite to form and no cytochrome P450 pathway doing the work, so the classic drug-induced liver injury mechanisms largely do not apply.
Why small molecules do
A non-peptide small molecule is metabolised the way conventional drugs are, largely in the liver, often producing metabolites. That is the same machinery through which most drug-induced liver injury arises. Making a GLP-1 agonist orally available by abandoning the peptide scaffold means accepting the toxicology profile of a conventional small molecule along with its convenience.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What happened with danuglipron
Pfizer discontinued it in April 2025 after a single asymptomatic participant in a dose-optimisation study experienced potential drug-induced liver injury that resolved on stopping. Across the wider safety database of more than 1,400 participants, liver enzyme elevations occurred at a frequency in line with approved agents in the class.
Why that distinction matters
Mild transaminase elevation is common and often clinically unimportant, many drugs cause it. A discrete case of apparent drug-induced liver injury is a different kind of observation, because idiosyncratic hepatotoxicity is rare, unpredictable and occasionally severe. The two are not points on one scale, and conflating them is the most common error in reading this literature.
What the class has to demonstrate now
Absence of hepatic signal at a scale large enough to detect a rare event. That is a demanding requirement: an adverse event occurring in roughly one in several thousand exposures cannot be excluded by a trial of a few hundred participants, however clean the result looks. It is why the aleniglipron Phase 2b's liver finding was reassuring rather than conclusive.
And why it is a licensed-medicine question only
Everything described here concerns investigational and licensed medicines assessed by regulators in registered trials. Orforglipron holds a UK marketing authorisation; aleniglipron does not; danuglipron never will. None of it relates to research material, which is not a GLP-1 receptor agonist and is not an alternative to any of these.
Frequently asked questions
Do injectable GLP-1 peptides carry the same liver risk?
The mechanism differs. Peptides are cleared by proteolysis and renal routes rather than the hepatic enzyme metabolism through which most drug-induced liver injury arises.
Are raised liver enzymes the same as liver injury?
No. Mild transaminase elevation is common and often unimportant; a discrete case of drug-induced liver injury is a rare, idiosyncratic and potentially serious event.
Does a clean Phase 2b rule out hepatotoxicity?
No. An event occurring in one in several thousand exposures cannot be excluded by a few hundred participants.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Hy's Law: How Trials Decide a Drug Hurt the LiverThree measurements and an exclusion. What Hy's Law is, why it predicts severe outcomes, and why raised enzymes alone mean very little.
- The Obesity Drug That Is Not an IncretinSetmelanotide targets the melanocortin-4 receptor, not GLP-1. An approved medicine for rare genetic obesity, and a different mechanism entirely.
- The Survodutide Comparison, Read ProperlyAn open-label semaglutide arm in a type 2 diabetes dose-finding trial. Why that is weaker evidence than a head-to-head, and what the numbers mean.
- Failing to Show Non-Inferiority Is Not Showing InferiorityREDEFINE 4 missed its non-inferiority endpoint. That is a specific statistical statement, and it is not the same as the drug being worse.
- Satiety and Nausea Run Through Different CircuitsA 2024 Nature paper showed hindbrain GLP-1 receptor circuits for satiety and aversion are dissociable. Nausea may not be the price of appetite suppression.